Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Hiddo J.L. Heerspink, Thomas A. Zelniker, Jamie P. Dwyer, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Eri T. Kato, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. SabatineItamar Raz

Cardiology
Internal Medicine

Research output: Contribution to journal › Article › peer-review

476 Scopus citations

Sort by
Weight
Alphabetically

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Fingerprint

Medicine & Life Sciences